Linzess (linaclotide) is a prescription medication approved by the Food and Drug Administration (FDA) to treat certain types of constipation. Most Medicare Part D plans provide coverage for the drug ...

FDA has announced it has approved Linzess (linaclotide) to treat chronic idiopathic constipation and to treat irritable bowel syndrome with constipation in adults, according to a news release. Linzess ...

The FDA has approved Linzess capsules for treating irritable bowel syndrome with constipation in pediatric patients seven years and older, according to a Nov. 5 news release. Here are five things to ...

Findings showed 30% of patients taking linaclotide 145mcg achieved the primary endpoint of combined responder. The Food and Drug Administration (FDA) has approved Linzess ® (linaclotide) for the ...

Shares of Ironwood Pharmaceuticals IRWD have witnessed a sharp decline over the past month, primarily due to softer sales of ...

Add Yahoo as a preferred source to see more of our stories on Google. In 2022, President Biden signed the Inflation Reduction Act into law, making it possible for the federal government to negotiate ...

Linzess is approved for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients aged seven years and above. The drug is also approved for treating ...

Shares of Ironwood Pharmaceuticals (IRWD) added ~31% on Friday to hit a new 52-week high after the company set its 2026 revenue outlook ahead of Street forecasts, citing higher net sales from Linzess, ...